Search results for "Exon"

showing 10 items of 437 documents

Missense Mutations in the Proline-Rich Region of Coagulation Factor XII in Hereditary and Idiopathic Angioedema.

2006

Abstract Hereditary angioedema (HAE) is characterized by recurrent skin swelling, abdominal pain attacks, and potentially life-threatening upper airway obstruction. The two classic HAE types (I and II) are caused by mutations in the complement C1 inhibitor gene, resulting in a functional deficiency of C1 inhibitor. Recently, a novel type of hereditary angioedema has been described, these patients showing normal C1 inhibitor concentration and activity in plasma (HAE with normal C1 inhibitor, HAE type III). With few exceptions, all reported patients have been women, and exposition to estrogens appears to be an important precipitating factor. Screening of twenty unrelated female patients with …

medicine.medical_specialtyFactor XIIMutationAngioedemabiologybusiness.industryImmunologyCell BiologyHematologyCoagulation Factor XIImedicine.disease_causemedicine.diseaseBiochemistryC1-inhibitorExonEndocrinologyInternal medicineHereditary angioedemamedicinebiology.proteinMissense mutationmedicine.symptombusinessBlood
researchProduct

FokI Polymorphism of the Vitamin D Receptor Gene Correlates with Parameters of Bone Mass and Turnover in a Female Population of the Italian Island of…

2005

One of the most promising genetic approaches to dissecting a multifactorial disease is represented by genetically isolated population studies. We studied a genetic marker in a cohort of women living on the Mediterranean island of Lampedusa, a geographically isolated population. Lampedusa, located between the African coast and Sicily, consists of a young genetic isolate (<20 generations) with an exponential growth in the last generations. We analyzed the association between the FokI vitamin D receptor (VDR) gene polymorphism, previously proposed as a predictor of bone mass, with parameters of bone mass and turnover in a cohort of pre- and postmenopausal women living on Lampedusa. In 424 wome…

medicine.medical_specialtyGenotypeBone densityEndocrinology Diabetes and MetabolismOsteoporosisCalcitriol receptorBone and BonesWhite PeopleCohort StudiesFokI polymorphism of the vitamin DEndocrinologyGene FrequencyBone DensityRisk FactorsInternal medicineGenotypemedicineHumansOrthopedics and Sports MedicineAllele frequencyOsteoporosis PostmenopausalUltrasonographyPolymorphism GeneticbiologyExonsMiddle Agedmedicine.diseaseFokIPostmenopauseEndocrinologyItalyPremenopauseOsteocalcinbiology.proteinReceptors CalcitriolFemaleGene polymorphismCalcified Tissue International
researchProduct

Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence

2018

BACKGROUND Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal. OBJECTIVE The aim of the present review was to describe the state of art of the pre-clinical research and the clinical evidence related to GHB used alone or in combination with other treatments in alcohol withdrawal syndrome and alcohol abstinence maintenance. METHOD Internationally published pre-clinical findings and clinical studi…

medicine.medical_specialtySodium Oxybatemedia_common.quotation_subjectClinical Biochemistry01 natural sciencesNaltrexone03 medical and health sciences0302 clinical medicinemedicineHumansmedia_common.cataloged_instance030216 legal & forensic medicineEuropean unionPsychiatrymedia_commonPharmacologyAlcohol Abstinencebusiness.industry010401 analytical chemistryGamma hydroxybutyrategamma-Hydroxybutyric acidAbstinencemedicine.diseaseSubstance Withdrawal Syndrome0104 chemical sciencesAlcohol withdrawal syndromeSodium OxybatebusinessAlcohol-Related DisordersCentral Nervous System AgentsAlcohol Abstinencemedicine.drugCurrent Drug Metabolism
researchProduct

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice

2012

Background & Aims CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo . Methods Mice with liver-specific deletion of CYLDexon7/8 ( CYLD FF xAlbCre ) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated …

medicine.medical_specialtyTumor suppressor geneBiliary Tract DiseasesIn Vitro TechniquesBiologymedicine.disease_causeDimethylnitrosamineDeubiquitinating Enzyme CYLDMiceRisk FactorsFibrosisInternal medicinemedicineAnimalsHomeostasisGenetic Predisposition to DiseaseHepatologyLiver NeoplasmsExonsTransforming growth factor betamedicine.diseaseFibrosisMice Mutant StrainsDeubiquitinating Enzyme CYLDMice Inbred C57BLGene expression profilingCysteine EndopeptidasesDisease Models AnimalPhenotypeEndocrinologyLiverPhenobarbitalHepatocellular carcinomaCancer researchbiology.proteinCell activationCarcinogenesisGene DeletionJournal of Hepatology
researchProduct

PGC-1 isoforms and their target genes are expressed differently in human skeletal muscle following resistance and endurance exercise

2015

The primary aim of the present study was to investigate the acute gene expression responses of PGC-1 isoforms and PGC-1a target genes related to mitochondrial biogenesis (cytochrome C), angiogenesis (VEGF-A), and muscle hypertrophy (myostatin), after a resistance or endurance exercise bout. In addition, the study aimed to elucidate whether the expression changes of studied transcripts were linked to phosphorylation of AMPK and MAPK p38. Nineteen physically active men were divided into resistance exercise (RE, n = 11) and endurance exercise (EE, n = 8) groups. RE group performed leg press exercise (10 9 10 RM, 50 min) and EE walked on a treadmill (~80% HRmax, 50 min). Muscle biopsies were ob…

medicine.medical_specialtybiologysplice variantPhysiologyVastus lateralis musclePGC-1αphysical activitySkeletal muscleta3141MyostatinMuscle hypertrophyExonmedicine.anatomical_structureEndocrinologyPGC1-1βMitochondrial biogenesisEndurance trainingPhysiology (medical)Internal medicineGene expressionmedicinebiology.proteinta315Original ResearchPhysiological Reports
researchProduct

Treatments for Opioid Dependence and Methadone

2016

Abstract This chapter is focused on opioid dependence treatment and is framed in a holistic perspective. Specifically, there are three main approaches to pharmacological treatment of opioid dependence: opioid detoxification, agonist maintenance, and antagonist maintenance. There is a great amount of evidence supporting the efficacy of methadone and buprenorphine or the combination of buprenorphine–naloxone for the treatment of opioid withdrawal and their clinical utility as pharmacotherapy in long-term maintenance programs. Secondary or adjunctive medications such as heroin, naltrexone, and alpha-2-adrenergics are also reviewed. The need for further research and to overcome nonscientificall…

medicine.medical_specialtybusiness.industry(+)-NaloxoneNaltrexoneHeroinPharmacotherapyOpioidDetoxificationMedicinebusinessIntensive care medicineBuprenorphinemedicine.drugMethadone
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct

Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years.

2018

Addiction pharmacotherapy aims to prevent drug abstinence symptoms, reduce drug craving and relapse, and normalize physiologic functions disrupted by chronic use of the drug. During the last 50 years, there has been an enormous revolution in pharmacotherapy for drug addiction. From abstinence as practically the only treatment option available, there are now multiple drugs on the market that have proved their efficacy in treating opiate and alcohol disorders. The present review will focus on the pharmacological treatments of the drugs whose consumption most affects individuals and society: alcohol and opiates. We will review the drugs most widely prescribed to prevent relapse and maintain ab…

medicine.medical_specialtymedia_common.quotation_subjectNaltrexone03 medical and health sciences0302 clinical medicineDrug DiscoverymedicineAnimalsHumans030212 general & internal medicineIntensive care medicineNalmefenemedia_commonPharmacologybusiness.industryAddictionAbstinenceOpioid-Related DisordersDrug AbstinenceAlcoholismAcamprosatebusiness030217 neurology & neurosurgeryBuprenorphinemedicine.drugMethadoneEuropean journal of pharmacology
researchProduct

Therapies in early development for the treatment of opiate addiction.

2015

Opiate drugs are psychoactive substances used to manage severe pain. However, their chronic use is associated with the development of addiction. Opiate addiction represents a significant public health concern.This review focuses on the most recent advances in the pharmacological treatment of opiate addiction, from those being tested in clinical trials (Phase I and II), to preclinical studies that point to new targets. Readers will gain knowledge of the wide variety of treatments used to treat opiate addiction, including their strengths and weaknesses, and the promising pharmacological targets identified by preclinical research.Among the currently available agonist therapies, new dosage form…

medicine.medical_specialtymedia_common.quotation_subjectNarcotic AntagonistsNaltrexonePharmacological treatmentmedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPsychiatrymedia_commonPharmacologybusiness.industryAddictionGeneral MedicineOpioid-Related DisordersNaltrexoneBuprenorphineClinical trialAnalgesics OpioidDrug DesignOpiate addictionOpiatebusinessmedicine.drugMethadoneBuprenorphineExpert opinion on investigational drugs
researchProduct

Does δ-sarcoglycan-associated autosomal-dominant cardiomyopathy exist?

2009

In this study we clinically and genetically characterize a consanguineous family with a homozygous novel missense mutation in the delta-sarcoglycan gene and a second delta-sarcoglycan mutation that has previously been reported to cause severe autosomal-dominant dilated cardiomyopathy. We identified a novel missense mutation in exon 6 (p.A131P) of the delta-sarcoglycan gene, which in a homozygous state leads to the clinical picture of a limb girdle muscular dystrophy. In four heterozygous carriers for the mutation, aged 3-64 years, a second sequence variant in exon 6 (p.S151A) of the delta-sarcoglycan gene was detected on the other allele. This second missense change had previously been repo…

musculoskeletal diseasesAdultCardiomyopathy DilatedMalemedicine.medical_specialtyAdolescentBiopsyDNA Mutational AnalysisCardiomyopathyMutation MissenseCompound heterozygosityArticleExonConsanguinityElectrocardiographyYoung AdultInternal medicineSarcoglycansGeneticsMedicineMissense mutationHumansMuscular dystrophyChildGenetics (clinical)Genes DominantGeneticsFamily Healthbusiness.industryMusclesMyocardiumDilated cardiomyopathyMiddle Agedmedicine.diseasePedigreeEndocrinologyEchocardiographyChild PreschoolMutation (genetic algorithm)FemalebusinessLimb-girdle muscular dystrophy
researchProduct